PD-L1 immunohistochemistry (IHC), microsatellite instability (MSI)/mismatch repair (MMR), Epstein–Barr virus (EBV), and tumor mutational burden (TMB) have been proposed as predictive biomarkers to predict response to ICIs in patients with GC [12,14]. Here, CD274 is linked to neoplasm.